Staff

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund...

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models...

Physician Scientist at Birthing Cultural Rigor Prioritizes Voices of Black Birthing Experience in Response to Obstetric Racism in the United States

MEMPHIS, Tenn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Black mothers die in hospitals at nearly four times the rate of White mothers...

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomasSINGAPORE, Sept. 14, 2022...

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models...

error: Content is protected !!